AA
TBPH icon

ALPS Advisors’s Theravance Biopharma TBPH Stock Holding History

ALPS Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$889K Buy
52,318
+11,062
+27% +$183K ﹤0.01% 732
2026
Q1 		$670K Sell
41,256
-352
-0.8% -$6.23K ﹤0.01% 653
2025
Q4 		$778K Buy
41,608
+17,394
+72% +$289K ﹤0.01% 633
2025
Q3 		$354K Sell
24,214
-2,793
-10% -$35.3K ﹤0.01% 934
2025
Q2 		$298K Sell
27,007
-9,072
-25% -$88.2K ﹤0.01% 936
2025
Q1 		$322K Sell
36,079
-3,680
-9% -$34.2K ﹤0.01% 880
2024
Q4 		$374K Buy
39,759
+2,323
+6% +$21.1K ﹤0.01% 737
2024
Q3 		$302K Sell
37,436
-508
-1% -$4.4K ﹤0.01% 956
2024
Q2 		$322K Buy
+37,944
New +$342K ﹤0.01% 814
2018
Q4 		– Sell
-97,513
Closed -$3.19M – 937
2018
Q3 		$3.19M Buy
97,513
+17,906
+22% +$488K 0.02% 198
2018
Q2 		$1.8M Buy
79,607
+7,043
+10% +$167K 0.01% 239
2018
Q1 		$1.76M Buy
72,564
+12,613
+21% +$346K 0.01% 221
2017
Q4 		$1.67M Buy
59,951
+6,938
+13% +$205K 0.01% 206
2017
Q3 		$1.81M Buy
53,013
+4,944
+10% +$162K 0.01% 196
2017
Q2 		$1.92M Buy
+48,069
New +$1.85M 0.01% 186
2015
Q2 		– Sell
-15,967
Closed -$277K – 689
2015
Q1 		$277K Buy
+15,967
New +$293K ﹤0.01% 627

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ALPS Advisors's TBPH Position: Q2 2026 in Review

ALPS Advisors increased its Theravance Biopharma (TBPH) stake by 27% in Q2 2026, buying an estimated $183K and bringing the position to 52,318 shares worth $889K. The position accounts for ﹤0.01% of the portfolio, ranked #732.

ALPS Advisors first reported a position in TBPH in Q1 2015 and has held it in 16 quarters since. The position peaked at $3.19M in Q3 2018. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • ALPS Advisors held 52,318 shares of Theravance Biopharma worth $889K as of Q2 2026.
  • ALPS Advisors bought 11,062 Theravance Biopharma shares in Q2 2026, an estimated $183K.
  • Theravance Biopharma made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #732 holding.
  • ALPS Advisors first reported a position in Theravance Biopharma in Q1 2015 and has held it in 16 quarters since.
  • ALPS Advisors's Theravance Biopharma position peaked at $3.19M in Q3 2018.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.